Amgen Announces FDA Advisory Committee Meeting To Review ABP 501, A Biosimilar Candidate To Adalimumab

THOUSAND OAKS, Calif., June 13, 2016 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the Company’s Biologics License Application (BLA) for ABP 501, a biosimilar candidate… http://www.prnewswire.com/news-releases/amgen-announces-fda-advisory-committee-meeting-to-review-abp-501-a-biosimilar-candidate-to-adalimumab-300283782.html